Colgate-Palmolive shares rise 5.07% premarket after Q4 results beat estimates, driven by strong sales and product launches.

Colgate-Palmolive

Colgate-Palmolive's 2030 Plan: A Strategic Growth and Productivity Program for Innovation, Digital Capabilities, and Omnichannel Demand Generation.

Colgate-Palmolive shares jump 5.49% after-hours on better-than-expected Q4 sales and raised 2026 guidance.

Freeport-McMoRan

Newmont

Tesla

US Stocks Plummet Amid Fed Leadership Uncertainty and Inflation Concerns

Colgate-Palmolive Achieves Growth Amid Challenges, Eyes Strategic Growth Markets

Catalyst<ul> <li>Most analysts rate CL Buy or Strong Buy, showing broad institutional optimism.</li> <li>Fund flows show positive net inflow across all order sizes indicating strong investor interest.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li></ul>

Key Factors

Colgate-Palmolive (CL) reported Q4 2025 earnings with $5.23 billion in net sales, a 5.8% year-over-year increase, driven by solid pricing and resilient demand in key international markets. CL swung to a $0.05 per-share loss in Q4 due to a $794 million impairment charge related to its underperforming skin health business, particularly in China. CL raised 2026 guidance, forecasting 1%–4% organic sales growth and double-digit EPS expansion, despite exiting its private label pet food business and facing macroeconomic headwinds. CL launched a 2030 Strategic Growth and Productivity Program focusing on innovation, digital capabilities, omnichannel demand generation, and organizational restructuring to improve profitability.

Recent Updates

CL News